Foundation Consumer Healthcare Adds #1 Selling Over-the-Counter SKU to Growing Portfolio of Diverse Health and Wellness Products

34-year industry veteran, Greg Bradley, joins Foundation Consumer
Healthcare as President and CEO

PITTSBURGH–(BUSINESS WIRE)–Foundation Consumer Healthcare (FCH), a company dedicated to improving
consumers’ lives by developing and growing a portfolio of differentiated
over-the-counter (OTC) products, has completed the acquisition of Plan B
One-Step® and several Value Brands of emergency contraception from Teva
Pharmaceutical Industries Ltd. in a $675 million transaction. Plan B
One-Step® is the #1 selling OTC SKU in the U.S. and helps prevent
unintended pregnancy when used as directed within 72 hours of
unprotected sex or birth control failure.

In support of the Plan B One-Step® acquisition, Greg Bradley has joined
FCH as President and CEO. With nearly 34 years of experience in the
consumer-packaged goods industry, Bradley has a proven track record of
improving in-market performance of existing OTC healthcare brands. Prior
to joining FCH, Bradley spent much of his career with GlaxoSmithKline
where he led multiple prescription to OTC product switches and in 2011,
Bradley founded Advantage Consumer Healthcare (ACH), a full-service
company specializing in OTC switches and healthcare product launches.
FCH will continue to work with ACH as their OTC selling team.

“As the #1 OB/GYN recommended OTC emergency contraceptive brand and an
important birth control option for women across the U.S., Plan B
One-Step® is the perfect addition to our growing portfolio,” stated
Bradley. “We look forward to devoting immense resources to support Plan
B One-Step® and working closely with our retail partners to ensure
continued access to this critical women’s health product.”

Formed in 2014, FCH markets a diverse portfolio of differentiated OTC
products including Neo-Synephrine®, Campho-Phenique®, Bronkaid®, St.
Joseph® Aspirin and Theravent®. With increased investment and category
growth, a commitment to innovation and an eye toward additional
acquisitions, the future is bright for FCH and its retail partners.

In addition to Bradley, FCH is led by industry veterans with nearly 80
years of collective experience in the development, marketing and
commercialization of prescription and OTC medicines at notable OTC
companies, including:

  • May Petracco, Chief Financial Officer
  • Steve Howard, Chief Marketing Officer
  • Tara Evans, Marketing Director of Women’s Health
  • Doug Lusby, Senior Vice President of Supply Chain Operations

“The senior leadership team at FCH is dedicated to supporting innovative
therapies and focused on driving growth across our product portfolio,”
said Bradley. “As the category leader, Plan B One-Step® plays an
important role in women’s health, and FCH is eager to invest the
resources and thinking necessary to help Plan B One-Step® fulfill that
role.”

About Foundation Consumer Healthcare

Formed in 2014, Foundation Consumer Healthcare (FCH) is dedicated to
improving consumers’ lives by developing and growing a portfolio of
differentiated over-the-counter (OTC) products including Plan B One
Step®, Theravent® Snore Therapy Strips, Campho-Phenique® Healing Gel &
Liquid, St. Joseph® 81 mg Aspirin, Bronkaid® Dual Action Asthma Caplets
and Neo-Synephrine® Nasal Spray. FCH’s management team is comprised of
industry leaders with unparalleled experience in the development,
marketing and commercialization of prescription and non-prescription
medicines. FCH is backed by Juggernaut Capital Partner and Kelso &
Company, two private equity firms with successful histories in the OTC
marketplace and commitment to building a diverse portfolio of brands
under the FCH banner. FCH is based in Pittsburgh, PA, with additional
team members located throughout the country. For additional information,
visit https://foundationch.com.

About Plan B One-Step®

Plan B One-Step® (levonorgestrel) 1.5 mg tablet is a progestin-only
emergency contraceptive that helps prevent pregnancy when taken within
72 hours (3 days) after birth control failure or unprotected sex. The
sooner it’s taken, the better it works. Plan B One-Step® works mainly by
stopping the release of an egg from the ovary. It is possible that Plan
B One-Step® may also work by preventing fertilization of an egg (the
uniting of sperm with the egg) or by preventing attachment
(implantation) to the uterus (womb). When used as directed, about 7 out
of every 8 women who would have gotten pregnant will not become pregnant
after taking Plan B One-Step®. Plan B One-Step® is not an abortion pill;
it will not work if a woman is already pregnant and will not affect an
existing pregnancy. Plan B One-Step® is a back-up method of preventing
pregnancy, and should not be used as regular birth control because it is
not as effective. Side effects may include menstrual changes, nausea,
lower stomach (abdominal) pain, tiredness, headache, dizziness, breast
pain and vomiting. Plan B One-Step® does not protect a woman against
HIV/AIDS or sexually transmitted diseases (STDs). For additional
information, visit www.PlanBOneStep.com.

Contacts

Rx Mosaic Health
Sara Baker, 212-485-6836
sbaker@rxmosaic.com